Boston Scientific buys Embolic Protection for $75 million
This article was originally published in Clinica
A week after spending $345 million to buy balloon catheter company Interventional Technologies, Boston Scientific has joined the list of large companies snapping up embolic protection devices. Boston is paying $75 million in cash for Campbell, Georgia-based Embolic Protection (EPI). Boston will also make undisclosed milestone payments.
You may also be interested in...
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.